|
Colorectal Cancer Drug Fizzles in Pivotal Phase III Trial
Aeterna Zentaris’ colorectal cancer drug perifosine did not meet its primary endpoint of median overall survival in a key Phase III trial, potentially putting the skids on the compound.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives